Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases. Its business centers on oncology and immunology products, including Revuforj and Niktimvo, supported by a pipeline of product candidates and collaboration arrangements.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved and marketed therapies sold in the United States, including Revuforj and Niktimvo.
Revenue recognized from co-commercialization and partner arrangements, including Incyte.
Investigational oncology and immunology programs being advanced through trials and regulatory work.
Products
Reported · share of revenue- Net Product Revenues72.4 %
- Collaboration Revenue24.6 %
- Milestone Revenue3.0 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Syndax sells primarily into the U.S. specialty pharmaceutical channel, where specialty distributors and specialty pharmacies resell products to healthcare providers and patients. Its commercial focus is on hematologists, oncologists, and transplant physicians, especially in academic and community treatment settings. Collaboration revenue also reflects partner-led commercialization and profit-sharing structures.
Buy Revuforj and distribute it onward to pharmacies and providers in the specialty drug channel.
Dispense oncology medicines and manage access, reimbursement, and patient fulfillment.
Prescribe Revuforj for eligible cancer patients based on clinical need and label.
Prescribe Niktimvo for chronic graft-versus-host disease after prior therapies fail.
Partners such as Incyte support global commercialization and revenue-sharing arrangements.
Strategy
Syndax’s strategy is to build a commercial franchise around Revuforj and Niktimvo while continuing to advance its clinical pipeline. The company relies on targeted specialty sales, partner-led commercialization outside the U.S., and outsourced manufacturing to keep its operating model focused on drug development and launch execution. It also seeks milestone, royalty, and collaboration economics from partnerships to broaden its revenue base.
Product sales and collaboration economics depend on successful launch execution and access.
The company lacks broad direct international infrastructure and uses partners to extend reach.
Future growth depends on additional approved products and label expansion.
Geography
Syndax is headquartered in the United States and its current commercial activity is concentrated there. The company also references the European Union and other major markets as future pricing and reimbursement environments for its products, reflecting potential international expansion through partners. Manufacturing is outsourced, so geography matters mainly through commercial access, regulatory approval, and third-party supply chains rather than owned production sites.
Risks
Syndax depends heavily on successful commercialization of a small number of products, so demand, reimbursement, and launch execution are central risks. It also faces typical biopharma risks such as clinical trial failure, regulatory setbacks, competition, manufacturing dependence on third parties, and pricing pressure from payors and government programs.
- Commercialization may underperform expectationsImpact: HighLikelihood: Medium
The company relies on Revuforj and Niktimvo adoption in specialty oncology channels.
Exposure: U.S. launch execution and market uptake
- Pricing and reimbursement pressureImpact: HighLikelihood: Medium
Government and third-party payors can limit net realized pricing and access.
Exposure - Clinical and regulatory failureImpact: HighLikelihood: Medium
Pipeline value depends on successful trials and approvals, which are uncertain.
Exposure: Product candidates and label expansion
- Competition in oncology and immunologyImpact: MediumLikelihood: Medium
Competing therapies can reduce market share and slow adoption.
Exposure - Third-party manufacturing dependenceImpact: MediumLikelihood: Medium
The company does not own manufacturing facilities and relies on contract manufacturers.
Exposure
Accounting
Judgemental itemsRevuforj revenue is recognized net of rebates, chargebacks, discounts, and returns.
Impact: Affects reported sales and gross-to-net volatility
Incyte is the principal in product sales and Syndax recognizes its share of profits or losses.
Impact: Affects collaboration revenue and operating results
R&D expense includes estimates for outsourced research and trial progress.
Impact: Can shift quarterly R&D expense timing
The Royalty Pharma agreement creates royalty interest expense tied to Niktimvo sales.
Impact: Affects financing costs and future cash flows
Trade payables in foreign currencies are revalued through other expense.
Impact: Can create non-operating volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Exelixis, Inc
EXEL · Biological Products, (No Diagnostic Substances)
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base.
Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Last updated: 24/09/2026